Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

cancer-patient-resting

DON’T BLAME RURAL CANCER PATIENTS FOR THEIR POORER HEALTH OUTCOMES

DON'T BLAME RURAL CANCER PATIENTS FOR THEIR POORER HEALTH OUTCOMES BY CHRISTOPHER CHENEY  |   AUGUST 23, 2018 The disparity between rural and urban cancer patients is best explained by differences in access...
New_FDA_Approval!

Imbruvica + rituximab becomes first non-chemo combination for Waldenström’s macroglobulinemia

Imbruvica + rituximab becomes first non-chemo combination for Waldenström’s macroglobulinemia The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for...
dna-strands-4x6-v2

Tailored Drug Cocktails Offer Hope to Kids with Aggressive Brain Tumors

Tailored Drug Cocktails Offer Hope to Kids with Aggressive Brain Tumors Clinical Trial Tests Personalized Treatments in Push to Improve Pediatric Cancer Survival By Suzanne Leigh on August 29, 2018 UCSF Benioff Children’s...

Fearless Friday: Radiation Part II: How radiation oncologists think about treatment options

Dr. Chad Rusthoven is back to discuss how treatments are selected for different types and stages of cancer. Please email us if there is anything we can do to help...
New_FDA_Approval!

FDA grants accelerated approval for 3rd line treatment of metastatic small cell lung cancer

FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer On August 16, 2018, the Food and Drug Administration granted accelerated approval to nivolumab (Opdivo, Bristol-Myers...
New_FDA_Approval!

FDA grants approval for 1st line treatment of metastatic nonsquamous NSCLC

FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC On August 20, 2018, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck...